Live Breaking News & Updates on கொலோனோஸ்கோபி

Stay updated with breaking news from கொலோனோஸ்கோபி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

New guidelines for colon cancer screenings say to get screened earlier

New guidelines say adults at average risk of colorectal cancer should be screened from ages 45 to 75. ....

United States , Associated Press , Journal Of The American Medical Association , Us Preventive Services Task , American Cancer Society , American Medical Association , Colon Cancer , ஒன்றுபட்டது மாநிலங்களில் , தொடர்புடையது ப்ரெஸ் , இதழ் ஆஃப் தி அமெரிக்கன் மருத்துவ சங்கம் , எங்களுக்கு ப்ரெவெஂடிவ் சேவைகள் பணி , அமெரிக்கன் புற்றுநோய் சமூகம் , அமெரிக்கன் மருத்துவ சங்கம் , பெருங்குடல் புற்றுநோய் ,

Woman's Doctor: Putting off colonoscopies could pose danger

A study by Epic Health Research Network found an 86% drop in that potential lifesaving test from January through April of last year. ....

Jeffery Nelson , Mercy Medical Center Dr , Epic Health Research Network , Mercy Medical Center , Woman 039s Doctor , ஜெஃப்பரி நெல்சன் , கருணை மருத்துவ மையம் டாக்டர் , காவியம் ஆரோக்கியம் ஆராய்ச்சி வலைப்பின்னல் , கருணை மருத்துவ மையம் ,

New Colorectal Cancer Screening Guidelines Are Here

); b.push( );for(var c=0;c
),b.push(a[c]),b.push( + script .toString()+ > );b.push( );b.push( ....

United States , Us Preventive Services Task , American Cancer Society , Services Task Force , Colorectal Cancer , Colon Cancer , Rectal Cancer , ஒன்றுபட்டது மாநிலங்களில் , எங்களுக்கு ப்ரெவெஂடிவ் சேவைகள் பணி , அமெரிக்கன் புற்றுநோய் சமூகம் , சேவைகள் பணி படை , பெருங்குடல் புற்றுநோய் , மலக்குடல் புற்றுநோய் ,

Average-risk Individuals May Prefer Stool-based Tests Over Colonoscopy for Colorectal Cancer Screening

PHILADELPHIA – When given a choice, most individuals with an average risk of colorectal cancer said they would prefer a stool-based screening test for colorectal cancer over colonoscopy, the method most often recommended by health care providers, according to results published in
Although colorectal cancer is the second most frequent cause of cancer-related death in the United States, about one-third of eligible American adults have never completed a colorectal cancer screening test, explained lead author Xuan Zhu, PhD, senior health services analyst at the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. Zhu added that colorectal cancer screening is particularly underutilized by individuals experiencing socioeconomic disadvantages, racial and ethnic minorities, and certain age groups. ....

United States , Xuan Zhu , National Opinion Research Center , American Association For Cancer Research , Science Of Health Care Delivery , University Of Chicago , Us Preventive Services Task Force , Cancer Prevention Research , Patriciae Kern Center , Sciences Corporation , American Association , Cancer Research , Mayo Clinic Robert , Health Care , Services Task Force , Hispanic Black , Exact Sciences Corporation , Cancer Screening , Colorectal Cancer , Clinical Medicine , Diagnostic Gastroenterology , Fecal Occult Blood , Large Intestine , Medical Tests , ஒன்றுபட்டது மாநிலங்களில் , தேசிய கருத்து ஆராய்ச்சி மையம் ,

Cosmo announces FDA approval of GI Genius intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy

(1)
DUBLIN, April 12, 2021 /PRNewswire/ Cosmo Pharmaceuticals NV (SIX: COPN) today announced the FDA approval of GI Genius intelligent endoscopy system, its revolutionary device for lesion detection during colonoscopy.
The GI Genius module FDA approval marks a pivotal milestone for Cosmo after more than 10 years of research and investments focused to generate disruptive innovations in the field of colon s disease and optimization of the colonoscopy procedure. The development of GI Genius intelligent endoscopy module has been possible thanks to the leadership position of Cosmo, its unique proprietary library of high-definition loss-less videos of colonoscopies and its proprietary software and algorithms. The device is the first of its kind to obtain the FDA approval through the De Novo application. The device operates in real time to assist the endoscopist in the detection of lesions, is very simple to use and is compatible with all endoscopes. Cosmo is the sole manufactu ....

United States , United Kingdom , Noord Holland , Fredc Andersen , Michael Wallace , Mauro Ajani , Falk Gmbh , Niall Donnelly , Cosmo Pharmaceuticals , Financial Services , Swiss Exchange , Prnewswire Cosmo Pharmaceuticals , European Union The Prospectus Directive , Redhill Biopharma Ltd , Mayo Clinic , Gastrointestinal Endoscopy , Redhill Biopharma , General Meeting , Swiss Code , Markets Act , Financial Promotion , European Union , European Economic Area , Prospectus Directive , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் ,